Drug Manufacturing Deals Shift to Europe Amid US Decline and Pharma Tariffs
Monday, April 13, 2026
In a striking development for the European pharmaceutical manufacturing sector, contract manufacturing deals for US FDA-approved drugs have surged in Europe, outpacing the United States by more than threefold in 2025. This shift comes despite ongoing pharma tariffs and represents the sharpest decline in US contract manufacturing contracts over the past five years.[1][3]
The trend underscores Europe's growing attractiveness as a hub for drug manufacturing, driven by factors such as robust infrastructure, skilled workforce, and strategic incentives. Industry analysts note that while US policies aimed at reshoring production have faltered, European contract development and manufacturing organizations (CDMOs) have capitalized on the opportunity, securing high-value deals that bolster the continent's position in the global supply chain.[1]
Key players in Europe's manufacturing ecosystem, including facilities in Italy and other key regions, are expanding capacities to meet this demand. For instance, recent announcements from companies like Axplora highlight investments in R&D and laboratory hubs, aligning perfectly with the influx of manufacturing contracts.[4] This movement not only diversifies supply chains but also mitigates risks associated with geopolitical tensions and tariff impositions.
From a strategic perspective, pharmaceutical executives are reevaluating partnerships, prioritizing stability and efficiency. The data reveals that last year marked a pivotal year, with Europe's deal volume exploding as US numbers plummeted. Experts attribute this to Europe's regulatory environment, which offers faster approvals and cost-effective operations compared to the increasingly complex US landscape burdened by tariffs and domestic policy shifts.[3]
Looking ahead, this trend is poised to reshape B2B partnerships across the pharma value chain. CDMOs in Europe are scaling up production lines for biologics, small molecules, and advanced therapies, positioning the region as a leader in resilient manufacturing. Companies involved report enhanced collaboration with US innovators seeking to derisk their supply chains amid economic uncertainties.
The implications extend to R&D investments, as European hubs integrate manufacturing closer to innovation centers, reducing time-to-market. This proximity fosters synergies in drug development, clinical trials, and commercialization, all critical for competitiveness in biopharma.[2]
Regulatory bodies in Europe are responding positively, streamlining processes to accommodate the boom. This includes updates to GMP standards and incentives for sustainable manufacturing practices, aligning with broader EU strategies for pharma sovereignty.
Industry leaders emphasize that this shift is not temporary; it's a structural change driven by economics and logistics. As US deal volumes hit record lows, Europe's CDMOs are reporting record highs, with projections for continued growth into 2026.
For pharma executives, this presents opportunities in joint ventures, technology transfers, and supply chain optimizations. Biotech innovators and drug manufacturers are advised to explore European partnerships to leverage these dynamics.
In summary, the pivot to Europe in drug manufacturing deals signals a new era of European dominance in global pharma production, offering stability amid US challenges. This evolution will influence everything from pricing strategies to innovation pipelines, ensuring Europe's pivotal role in life sciences.[1][3]
Further details highlight specific deals involving advanced modalities, where European expertise in handling complex formulations gives a competitive edge. Supply chain experts predict that by mid-2026, Europe could capture over 40% of global CDMO market share for FDA drugs.
The sector's resilience is evident in its ability to navigate tariffs, with diversified sourcing and localized production minimizing impacts. This positions Europe as the go-to destination for B2B pharma collaborations.
